Cite
HARVARD Citation
Wollin, L. et al. (2019). Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis–associated interstitial lung disease. Journal of scleroderma and related disorders. 4 (3), pp. 212-218. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Wollin, L. et al. (2019). Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis–associated interstitial lung disease. Journal of scleroderma and related disorders. 4 (3), pp. 212-218. [Online].